Abstract: It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Abstract: The use of compounds of the formula 1

Abstract: N-substituted dithiocarbamate esters, pharmaceutical compositions containing them, and methods of treating hyperproliferative disorders such as cancer by administering the N-substituted dithiocarbamate esters.

Abstract: Isolated nucleic acid molecules encoding human MEKK2, and isolated human MEKK2 proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a human MEKK2 transgene. The invention further provides human MEKK2 fusion proteins and anti-human MEKK2 antibodies. Methods of using the human MEKK2 proteins and nucleic acid molecules of the invention are also disclosed, including methods for detecting human MEKK2 activity in a biological sample, methods of modulating human MEKK2 activity in a cell, and methods for identifying agents that modulate the activity of human MEKK2.

Abstract: The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.

Abstract: N-substituted dithiocarbamate esters in which the amine function bears a hydrogen are provides, as are methods for using the compounds in the treatment of cellular hyperproliferation and VCAM-1 mediated disease. Particularly provided is a method of treating a hyperproliferative disorder such as cancer comprising administering an antiproliferative agent in combination with a potentiating effective amount of a N-substituted dithiocarbamate ester. Also provided are methods of using the compounds in the treatment of VCAM-1 mediated diseases such as inflammation and carrdiovascular disease.

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Abstract: It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Abstract: Isolated nucleic acid molecules encoding human MEKK2, and isolated human MEKK2 proteins, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a human MEKK2 transgene. The invention further provides human MEKK2 fusion proteins and anti-human MEKK2 antibodies. Methods of using the human MEKK2 proteins and nucleic acid molecules of the invention are also disclosed, including methods for detecting human MEKK2 activity in a biological sample, methods of modulating human MEKK2 activity in a cell, and methods for identifying agents that modulate the activity of human MEKK2.

Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Abstract: This invention is a method and composition for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amount of an ester of probucol.